Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.

The tolerability and efficacy of four courses of paclitaxel and ifosfamide plus cisplatin every 3 weeks was evaluated in patients with residual or refractory ovarian cancer. Additionally, supportive haematological effects of recombinant human interleukin 3 (rhIL-3) and recombinant human granulocyte...

Descripción completa

Detalles Bibliográficos
Autores principales: Veldhuis, G. J., Willemse, P. H., Beijnen, J. H., Boonstra, H., Piersma, H., van der Graaf, W. T., de Vries, E. G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063352/
https://www.ncbi.nlm.nih.gov/pubmed/9043028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063352/
https://www.ncbi.nlm.nih.gov/pubmed/9043028

Ejemplares similares